Cytochrome P450 (CYP) 7B1 is involved in many metabolic processes including androgen metabolism. Genetic variation in the CYP7B1 gene may play a role in predisposition to prostate cancer. Here, we screened the human CYP7B1 gene for possible polymorphisms. Only one single polymorphism was detected, a C-G change in the promoter -104 base pair from the transcription start site. The allele frequency was investigated in Swedish men and compared to a Korean population, as it is known that the frequency of prostate cancer is low among Orientals. We found that the frequency of the G-allele was 4.04% in Swedes (n ¼ 150) but only 0.33% among Koreans (n ¼ 153). Computer analysis indicated that the two variants bind with different affinities to a CCAAT-box binding protein. Expression studies with reporter constructs showed significantly higher transcriptional activity of the G variant in Hek293 cells (2.7-fold, Po0.05). In conclusion, we report here for the first time the detection of a single polymorphism in the CYP7B1 gene. This polymorphism is associated with phenotypic differences in an expression system and a widely different allele frequency in two ethnic populations, with great differences in the incidence of prostate cancer. 1 Weihua et al 2 demonstrated that 5a-androstane-3b,17b-diol (3bAdiol) is an endogenous ER b ligand. Cytochrome P450 (CYP) 7B1 and 3b-hydroxysteroid dehydrogenase (3b-HSD) are two enzymes that may determine the 3bAdiol levels available at the ER b and hence affect the regulation of prostate proliferation. CYP7B-knockout mice show lower proliferation rate of the prostate compared to the WT-mice.
INTRODUCTION
Recent studies indicate that the estrogen receptor b (ER b ) exhibits antiproliferative action in prostate, possibly balancing the stimulatory effect of ERa. 1 Weihua et al 2 demonstrated that 5a-androstane-3b,17b-diol (3bAdiol) is an endogenous ER b ligand. Cytochrome P450 (CYP) 7B1 and 3b-hydroxysteroid dehydrogenase (3b-HSD) are two enzymes that may determine the 3bAdiol levels available at the ER b and hence affect the regulation of prostate proliferation. CYP7B-knockout mice show lower proliferation rate of the prostate compared to the WT-mice. 3 Polymorphisms in the 3b-HSD gene have been associated with prostate cancer risk. 4, 5 CYP7B1 is known to be involved in the synthesis of bile acids from cholesterol. Two pathways have been described (see Chiang 6 for a review). One is the neutral or microsomal pathway and involves an initial 7alpha hydroxylation of cholesterol by CYP7A. The second is the acidic or mitochondrial pathway initiated by CYP27, which transforms cholesterol into 27-hydroxycholesterol that is further metabolized by CYP7B1. 7, 8 CYP7B1 is widely expressed in humans being particularly abundant in liver, brain and kidney. 9 The human CYP7B1 gene consists of six exons and shares the intron-exon organization with the CYP7A1 gene. It is located on chromosome 8q21.3 in close linkage to the CYP7A1 gene, suggesting that these genes have evolved via gene duplication. 10 The human CYP7B1 promoter is GCrich and contains three GC-boxes essential for the basal transcription.
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No common polymorphism has been reported in the human CYP7B1 gene to date. In this study, we used the human expressed sequence tag (EST) database to search for polymorphisms in the CYP7B1 gene together with singlestrand conformation polymorphism (SSCP) analysis. One C-G substitution in the 5 0 -region was discovered. Allele frequencies were determined in relation to risk for prostate cancer as well as in two different ethnic groups with high or low morbidity in this disease, namely in Swedes and Korean individuals. Finally, the activity of the various promoter variants was evaluated in a reporter system. Table 1 shows the putative new polymorphisms resulting in nonconservative amino-acid changes in the CYP7B1 gene according to a BLAST search. None of the indicated polymorphisms could be verified by direct sequence analysis.
RESULTS

Detection of a Promoter Polymorphism
However, SSCP analysis was carried out on all exons and the promoter region, using DNA from 12-30 individuals in order to investigate any common polymorphic alleles in the CYP7B1 gene. No polymorphisms were detected in the coding parts of the gene. SSCP analysis of the promoter region showed an altered electrophoretic pattern in one of 12 subjects (Figure 1 ). Sequence analysis revealed a C-G substitution at nucleotide position -104 from the transcription start site (as numbered in GenBank accession #AF127089). A computerized analysis by the transcription factor database search program, MatInspector 2.2 12 indicated that the affinity for the CCAAT-box binding proteins (C/EBP) should differ between the two promoter variants. The C-G alteration at -104 creates a putative C/EBPb binding site.
Transcriptional Activity of the Promoter Variants
To determine whether the polymorphism in the human CYP7B promoter will affect the transcription of the gene, PCR amplified fragments of À194 to þ 39 region numbering from the transcription start site, with either a C or a G at the polymorphic site were obtained from two homozygous individuals and subcloned into pGL3-Enhancer Luciferase vector. As shown in Figure 2 , a 2.7-fold higher normalized luciferase activity was observed for the pGL3G as compared to pGL3C in Hek293 cells. No significant difference was detected in HepG2 cells (data not shown). Hek293 and HepG2 cells were chosen due to high CYP7B promoter activity, as well as the high abundance of the C/EBP transcription factor in these tissues. 
Determination of the Allele Frequency
We could genotype all Swedish Caucasians but failed to genotype two Korean individuals, despite several attempts. The frequency of the uncommon allele among Swedish Caucasians controls was 4.04%, which should be compared to the allele frequency among Koreans, which was only 0.33 percent (w 2 -test, P ¼ 0.002) ( Table 2 ). There was no difference in the genotype or allele frequency between cases of prostate cancer and Swedish control subjects (Table 3) . DISCUSSION CYP7B1, together with 3a-HSD, 3b-HSD and 5a-RED are enzymes known to determine the levels of androgens and their metabolites. Genetic variations in these genes are important to study in human populations in order to understand the ethnic differences observed in prostate cancer incidence. Here, we have identified a C-G substitution in the 5 0 -region by SSCP analysis. A striking interethnic difference in the allele frequency was found between a Swedish and a Korean population sample. The two variants show different affinity for the CCAAT-box enhancer protein C/EBPb, as indicated by a computer analysis. We observed a difference between the mutant variants in promoter activity in Hek293 cells. Our results are consistent with a previous promoter study 9 showing that the inclusion of the CCAATbox increases the promoter activity in Hek293 by approximately 20% whereas no enhancement of the activity was observed with HepG2 cells. The well-characterized protein C/EBPb is a transcription factor known to bind to the CCAAT-box element required for the basal expression of many TATA-less genes. 13 It is also involved in different regulatory events such as apoptosis, inflammation and is known to interact with many other factors such as Ap1 and NFkB to regulate gene expression (reviewed by Ramji and Foka 14 ) . Variation in the abundance of C/EBPb and/ or other proteins between HepG2 and Hek293 cells could explain the different pattern observed in promoter activity of the polymorphic variants. Further studies, for example, EMSA are required to evaluate the exact transcriptional mechanism behind the altered transcription activity of the CYP7B promoter observed in Hek293 cells.
The reason for not identifying the predicted polymorphisms in our population is most likely that CYP7B1 cDNA sequences are poorly represented in the EST database. The likelihood of detecting polymorphisms increases if the gene of interest is represented by a greater number of full-length cDNAs from different cDNA libraries representing a larger number of individuals. 15 The CYP7B1 enzyme demonstrates a broad substrate specificity towards oxysterols, neurosteroids and sex hormones. 9 The enzyme has been implicated to play a role in diseases such as prostate cancer 3 and atherosclerosis. 16 Here, we show for the first time a polymorphism in the CYP7B1 gene that is associated with an altered promoter activity. The fact that the promoter polymorphism identified here is associated with an altered phenotype provides an important SNP tool for future association studies. In order to study the possible influence of this polymorphism in the development of prostate cancer, we determined the allele-frequency in prostate cancer patients and in matched healthy individuals. We could not find any significant association between the genotype and prostate cancer. However, since the genotype frequency was quite low this could be due to lack of statistical power.
The significant difference in allele frequencies observed between Swedes and Koreans may indicate a role of this polymorphism in the development of prostate cancer. This is a common disease among Caucasians (incidence 88 per 100 000 among Swedish men in 2001) (The Cancer Registry. Cancer incidence in Sweden 2001. Stockholm: National Board of Health and Welfare. 2003) but uncommon among Asians (incidence 10.1 per 100 000 in South Koreans from 1985 to 1999). 17 If the CYP7B1 enzyme is of importance for the activity of ER b through modulation of its important 3bAdiol ligand concentration, our results are consistent with this theory. The luciferase reporter system has demonstrated a higher activity of the G-variant, which is more common in Caucasians, and would then reduce the ligand concentration. Further and larger studies are needed to confirm such an association. Since the allele frequency among Swedes of this polymorphism was low (4.04%) it will not play a major role in the development of prostate cancer in this population. It is most likely that alterations in multiple genes 18 Other mechanisms that regulate the expression of CYP7B1, such as epigenetic regulation, may contribute to the promotion of prostate cancer growth.
MATERIALS AND METHODS
In Silico Analysis
Potential polymorphisms in the CYP7B1 gene were identified using the EST database and a BLAST alignment tool as previously described. 15, 19, 20 When the indicated mutations (Table 1 ) gave rise to a nonconservative amino-acid change, we performed a PCR-direct sequence analysis in 10 subjects to verify these potential polymorphisms.
Single-stranded Conformation Polymorphism Analysis
SNPs in the CYP7B1 gene were analysed by PCR-singlestranded conformation polymorphism (SSCP) analysis in a Swedish population. PCR reactions were performed with 2 U Taq-Polymerase (Applied Biosystem), 0.15 mM dNTP (Amersham), genomic DNA (0.1 mg) using primers listed in Table 4 . Amplification of the GC-rich exon 1 required the use of a GC-kit (Clontech). PCR was carried out in 30 cycles, each involving denaturation at 941C for 1 min, annealing (temperature see Table 4 ) for 45 s and extension at 721C for 45 s. The PCR products were verified in an ethidium bromidestained agarose gel. For the analysis, 3 ml of the PCR products was mixed with 27 ml loading buffer, containing 95% formamide, 20 mM EDTA, and 0.05% bromophenol blue. Before loading, the samples were denatured at 1001C for 5 min and cooled on ice. Electrophoretic separation of single-stranded DNA fragments was then analysed in 8.5% polyacrylamide gels. The gels were run in 2 Â Tris-borate-EDTA buffer at 41C for 3-6 h at 140 V. The DNA fragments were visualized by silver staining (PlusOne DNA Silver Staining Kit, Amersham). The PCR products were purified using PCR purification kit (Qiagen) and sequence analysed using Big Dye Terminator Kit v2 (Applied Biosystem) and an ABI Prism 377 DNA sequencer.
Study Population and Sample Selection
The study design was a population based case-control study of 337 Caucasians living in the county of Ö rebro in Sweden. The cases were 176 patients, age 51-79 years, with prostate cancer, who were recruited consecutively between May 1994 and February 1996. In all, 81% agreed to participate. The controls were men, who were randomly selected every 3 months from the county population register and frequency matched for age (50-59, 60-69 and 70-79 years). They were asked to participate by mail and 161 individuals agreed to participate, giving a response rate of 79%. Further description of the study population has been already published since this study population has been utilized in the evaluation of other polymorphisms involved in the androgen metabolism. [21] [22] [23] The Ethics Committee of the Regional Hospital of Ö rebro/Uppsala University, Sweden approved the study and all patients gave informed consent to participate.
In another part of the study, we investigated 156 Korean individuals randomly selected from two previous studies. 24, 25 The DNA samples were decoded and no data were available about those individuals concerning prostate cancer morbidity or heredity. The population consisted of healthy unrelated men and women from different areas in Korea. The Ethics committee of Karolinska Institutet at Huddinge University Hospital approved this part of the study.
PCR Assay
Blood samples were collected in tubes containing EDTA and stored at À201C. DNA was extracted using standard procedures and stored at À201C until analysed.
The fluorogenic 5 0 nuclease polymerase chain reaction (TaqMan s ) was employed for genotyping according to the principle reviewed by Livak et al. 26 We used a PE Applied Biosystems (Foster City, CA) ABI Prism s 7700 Sequence Detector. Reagents and optical 96-well plates used in the assay were purchased from PE Applied Biosystems.
The design of primers and probes was performed using Perkin Elmer s Primer Expresst Software Primers, and probes The Taqman s MGB probe 1 was labelled in the 5 0 end with fluorescent dye 6-FAM and the Taqman s MGB probe 2 with fluorescent dye VIC. The reactions were prepared in a 96-well format using a TaqMan s Universal Master Mix, 5 ng genomic DNA, 0.45 mM of each primer and 0.075 mM of each probe. The thermal cycling started with 2 min at 501C, followed by 951C for 10 min and finally 37 cycles were taken through 951C for 15 s and 601C for 1 min.
The data from the ABI Prism s 7700 Sequence Detector were plotted in a graph in which the outcome and quality of the allelic discrimination, was assessed. Nontemplate controls were used for detection of DNA contamination, but no such contamination was detected during the investigation.
Genotype and allele associations were assessed with w 2 test, binary and nominally logistic regression using Minitab s statistical software package (version 12.1, Minitab Inc., USA).
Cell Culture
HepG2 cells were cultured in MEM, 10% heat-inactivated fetal calf serum, nonessential amino acids and 1 mM sodium pyruvate. Hek293 cells were cultured in MEM, 5% fetal bovine serum and 1 mM sodium pyruvate. All culture media and their ingredients were obtained from Invitrogen.
Gene Reporter Constructs
Two CYP7B promoter-containing plasmids were constructed by PCR amplification using human genomic DNA as template with the forward and reverse promoter primers (Table 4) , a region known to include the cis-acting elements required for the basal expression. 11 The PCR reactions were carried out using the same conditions as described above. The 233 bp products were then subcloned into a pCR2.1 vector (Invitrogen), cleaved with KpnI and XhoI, gel purified (Qiagen) and subcloned into KpnI/XhoI sites of pGL3-Enhancer Luciferase vector (Promega), resulting in the constructs pGL3C and pGL3G, respectively. The sequences were verified by sequence analysis as described above. Plasmids were purified using the Qiagen Endotoxin Free kit. Plasmids used were from different purifications in order to exclude differences in plasmid quality.
Transfection Assay
Cells were plated in 35 mm six-well plates at a density of 2 Â 10 5 cells/well and incubated overnight. HepG2 and Hek293 cells were transfected using 20 ml Transfectin (Invitrogen), 5 mg of pGL3-enhancer plasmid and 5 mg of b-galactosidase vector (Promega). The cells were incubated in serum-free media at 371C for 3-5 h. The transfection solution was then replaced with fresh media containing serum. Cells were harvested 48 h later and luciferase and b-galactosidase activity were determined according to the manufacturer's description (Promega). b-Galactosidase values were corrected for endogenous cellular galactosidase activity.
